FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma

References

• Shi T, Ma Y, Yu L, et al. Cancer immunotherapy: A focus on the regulation of immune checkpoints. Int J Mol Sci. 2018;19:1389.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018;6:8.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm610670.htm
   Google Scholar
• First Anti-PD-L1 Drug Approved for NSCLC. Cancer Discov. 2016;6(12):OF1.
   Google Scholar
• Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. J Clin Pathol. 2018;71(3):189–194. doi: 10.1136/jclinpath-2017-204853.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. doi: 10.1126/science.1079490.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22(3):329–341.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380. doi: 10.1200/JCO.2006.05.9584.
   PubMed Web of Science ®Google Scholar
• Bignone PA, Banham AH. FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther. 2008;8(12):1897–1920. doi: 10.1517/14712590802494022.
   PubMed Web of Science ®Google Scholar
• Karnik T, Kimler BF, Fan F, Tawfik O. PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Hum Pathol. 2018;72:28–34. doi: 10.1016/j.humpath.2017.08.010.
   PubMed Web of Science ®Google Scholar
• Ding Y, Xu J, Bromberg JS. Regulatory T cell migration during an immune response. Trends Immunol. 2012;33(4):174–180. doi: 10.1016/j.it.2012.01.002.
   PubMed Web of Science ®Google Scholar
• Eikawa S, Ohue Y, Kitaoka K, et al. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol. 2010;185(11):6734–6740. doi: 10.4049/jimmunol.1000225.
   PubMed Web of Science ®Google Scholar
• Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758835918763493. doi: 10.1177/1758835918763493.
   Web of Science ®Google Scholar
• Joshi NS, Akama-Garren EH, Lu Y, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 2015;43(3):579–590. doi: 10.1016/j.immuni.2015.08.006.
   PubMed Web of Science ®Google Scholar
• Phillips JD, Knab LM, Blatner NR, et al. Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer. Cancer Immunol Immunother. 2015;64(9):1185–1191. doi: 10.1007/s00262-015-1725-1.
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–365. doi: 10.1146/annurev.iy.12.040194.002005.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455–458.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Suzuki H, Yamaura T, et al. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2(5):685–694. doi: 10.3892/mco.2014.299.
   PubMedGoogle Scholar
• Bacchetta R, Barzaghi F, Roncarolo MG. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. 2018;1417(1):5–22. doi: 10.1111/nyas.13011.
   PubMed Web of Science ®Google Scholar
• Usó M, Jantus-Lewintre E, Bremnes RM, et al. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget 2016;7:52849–52861.
   PubMedGoogle Scholar
• Kadota K, Nitadori JI, Adusumilli PS. Prognostic value of the immune microenvironment in lung adenocarcinoma. Oncoimmunology 2013;2(5):e24036. doi: 10.4161/onci.24036.
   PubMed Web of Science ®Google Scholar
• Zhang GQ, Han F, Fang XZ, Ma XM. CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis. Asian Pac J Cancer Prev 2012;13(8):3955–3960.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–590. doi: 10.1097/JTO.0b013e3181d60fd7.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. Jco. 2013;31(4):490–498. doi: 10.1200/JCO.2012.45.2052.
   PubMed Web of Science ®Google Scholar
• Tao H, Mimura Y, Aoe K, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75(1):95–101. doi: 10.1016/j.lungcan.2011.06.002.
   PubMed Web of Science ®Google Scholar
• Bonanno L, Pavan A, Dieci MV, et al. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes. Eur J Cancer. 2018;101:191–200. doi: 10.1016/j.ejca.2018.06.023.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 2006;15:1315–1319.
   PubMed Web of Science ®Google Scholar
• Shabaneh TB, Molodtsov AK, Steinberg SM, et al. Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Cancer Res. 2018;78(17):5038–5049. doi: 10.1158/0008-5472.CAN-18-0365.
   PubMed Web of Science ®Google Scholar
• Rubinkiewicz M, Migaczewski M, Hankus J, et al. The number of regulatory Foxp3+ T-cells in different stages of malignant transformation of large intestinal polyps. Adv Med Sci. 2016;61(2):306–310. doi: 10.1016/j.advms.2016.03.008.
   PubMed Web of Science ®Google Scholar
• Demoulin S, Herfs M, Somja J, Roncarati P, Delvenne P, Hubert P. HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells. Int J Cancer. 2015;137(2):345–358. doi: 10.1002/ijc.29389.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang Z, Han J, Qiu X, Pan J, Chen J. Increased frequency of CD4+ CD25+ FOXP3+ cells correlates with the progression of 4-nitroquinoline1-oxide-induced rat tongue carcinogenesis. Clin Oral Investig. 2014;18(7):1725–1730. doi: 10.1007/s00784-013-1146-5.
   PubMed Web of Science ®Google Scholar
• Silva MA, Ryall KA, Wilm C, Caldara J, Grote HJ, Patterson-Kane JC. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PLoS One. 2018;13(6):e0196464. doi: 10.1371/journal.pone.0196464.
   PubMed Web of Science ®Google Scholar
• Kuipers H, Muskens F, Willart M, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol. 2006;36(9):2472–2482. doi: 10.1002/eji.200635978.
   PubMed Web of Science ®Google Scholar
• DiDomenico J, Lamano JB, Oyon D, et al. The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. Oncoimmunology 2018;7(7):e1448329. doi: 10.1080/2162402X.2018.1448329.
   PubMed Web of Science ®Google Scholar